Record 7792   View: Standard Glossary  HistCite Guide
Author(s): Veber DF; Johnson SR; Cheng HY; Smith BR; Ward KW; Kopple KD
Title: Molecular properties that influence the oral bioavailability of drug candidates
Source: JOURNAL OF MEDICINAL CHEMISTRY 45 (12): 2615-2623
Date: 2002 JUN 6
Document Type: Journal : Article
DOI:  
Language: English
Comment:  
Address: GlaxoSmithKline, Dept Med Chem, King Of Prussia, PA 19406 USA.
GlaxoSmithKline, Dept Cheminformat, King Of Prussia, PA 19406 USA.
GlaxoSmithKline, Dept Computat & Struct Sci, King Of Prussia, PA 19406 USA.
GlaxoSmithKline, Dept Drug Metab & Pharmacokinet, King Of Prussia, PA 19406 USA.
Reprint: Veber, DF, GlaxoSmithKline, Dept Med Chem, 709 Swedeland Rd,POB 1539,
King Of Prussia, PA 19406 USA.
E-mail: veberdf@comcast.net
Author Keywords:  
KeyWords Plus: MEMBRANE PERMEATION ASSAY; INTESTINAL-ABSORPTION; SURFACE PROPERTIES; P-GLYCOPROTEIN; PREDICTION; PERMEABILITY; PEPTIDES; MODEL; SOLUBILITY; DISCOVERY
Abstract: Oral bioavailability measurements in rats for over 1100 drug candidates studied at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) have allowed us to analyze the relative importance of molecular properties considered to influence that drug property. Reduced molecular flexibility, as measured by the number of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of molecular weight. That on average both the number of rotatable bonds and polar surface area or hydrogen bond count tend to increase with molecular weight may in part explain the success of the molecular weight parameter in predicting oral bioavailability. The commonly applied molecular weight cutoff at 500 does not itself significantly separate compounds with poor oral bioavailability from those with acceptable values in this extensive data set. Our observations suggest that compounds which meet only the two criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area equal to or less than 140 Angstrom(2) (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat. Data sets for the artificial membrane permeation rate and for clearance in the rat were also examined. Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a negative effect on the permeation rate. A threshold permeation rate is a prerequisite of oral bioavailability. The rotatable bond count does not correlate with the data examined here for the in vivo clearance rate in the rat.
Cited References:
AJAY, 1998, J MED CHEM, V41, P3314
BURTON PS, 1996, J PHARM SCI-US, V85, P1336
CHATURVEDI PR, 2001, CURR OPIN CHEM BIOL, V5, P452
CHENG HY, UNPUB
CLARK DE, 1999, J PHARM SCI, V88, P807
CLARKE SE, 1994, CHEM RES TOXICOL, V7, P836
CLARKE SE, 2001, XENOBIOTICA, V31, P591
EGAN WJ, 2000, J MED CHEM, V43, P3867
ERTL P, 2000, J MED CHEM, V43, P3714
GAO J, 2001, J PEPT RES, V57, P316
GILMAN AG, 1990, GOODMAN GILMANS PHAR
GOODWIN JT, 1999, J PEPT RES, V53, P355
HARDMAN JG, 2001, GOODMAN GILMANS PHAR
HIRSCHMANN R, 1998, PEPTIDES 1996, P3
KANSY M, 1998, J MED CHEM, V41, P1007
LIN JH, 1999, PHARMACOL REV, V51, P135
LIPINSKI CA, 1997, ADV DRUG DELIVER REV, V23, P3
LIPINSKI CA, 2000, J PHARMACOL TOXICOL, V44, P235
MARQUIS RW, 2001, J MED CHEM, V44, P1380
MATHENY CJ, 2001, PHARMACOTHERAPY, V21, P778
NAVIA MA, 1996, DRUG DISCOV TODAY, V1, P179
OKUMU FW, 1997, PHARM RES-DORD, V14, P169
PALM K, 1996, J PHARM SCI, V85, P32
PALM K, 1997, PHARMACEUT RES, V14, P568
SMITH AB, 1997, J MED CHEM, V40, P2440
STENBERG P, 1999, PHARMACEUT RES, V16, P205
STENBERG P, 2000, J CONTROL RELEASE, V65, P231
STENBERG P, 2001, J MED CHEM, V44, P1927
SUDOH M, 1997, PHARMACOL RES S, V26, P14
SUGANO K, 2001, J BIOMOL SCREEN, V6, P189
SUGAWARA M, 1998, J PHARM SCI, V87, P960
THOMPSON M, 1982, ANAL CHEM, V54, P76
VEBER DF, 2000, PEPTIDES 2000, P113
WOHNSLAND F, 2001, J MED CHEM, V44, P923
YOSHIDA F, 2000, J MED CHEM, V43, P2575